Source comparison
Tesamorelin Protocol Comparison: Standard vs Age-Adjusted (50+)
Starting Dose 2mg daily subcutaneous 1mg daily subcutaneous Reduced hepatic GH receptor density requires lower initial dose to assess IGF-1 conversion capacity Titration Timeline Fixed dose, no routine adjustment Dose adjusted at weeks 4 and 12 based on IGF-1
This comparison does not assign a generated winner or score.
- Starting Dose
- 2mg daily subcutaneous
- 1mg daily subcutaneous
- Reduced hepatic GH receptor density requires lower initial dose to assess IGF-1 conversion capacity
- Titration Timeline
- Fixed dose, no routine adjustment
- Dose adjusted at weeks 4 and 12 based on IGF-1 response
- Age-related variability in receptor function makes individualized titration essential
- Target IGF-1 Range
- 250–320 ng/mL
- 220–280 ng/mL
- Lower target reduces glucose dysregulation risk while preserving metabolic benefits
- Glucose Monitoring
- Optional baseline check
- Mandatory at baseline, weeks 4, 12, 24, then every 6 months
- Higher risk of insulin resistance and impaired fasting glucose in 50+ age group
- Thyroid Assessment
- Not routinely required
- Mandatory baseline TSH and free T4
- Subclinical hypothyroidism impairs hepatic IGF-1 conversion. Correction improves response rates
- Expected VAT Reduction (12 months)
- 15–20% from baseline
- 10–15% from baseline
- Lower GH receptor density and slower metabolic turnover reduce fat loss velocity in older cohorts